Takeda Pharmaceuticals has named Julie Kim as the first woman to lead the 244-year-old Japanese drugmaker, a rarity in senior management in the world’s fourth-largest economy. Kim, a US citizen ...

Tokyo, Jan. 30 (Jiji Press)--Japan's Takeda Pharmaceutical Co. said Thursday that its president and CEO, Christophe Weber, will step down at its general shareholders meeting in June 2026.

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S. business unit. As part of the executive transition, Weber will retire in June ...

TOKYO -- Japanese trading house Marubeni has agreed to invest in Phillips Pharma Group, which supplies medical goods in sub-Saharan Africa. The investment marks Marubeni's entry into the African ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as the company upped its full-year profit outlook ...

This has now turned into much more, namely the aforementioned investment of 5 million US dollars. Marubeni’s strategic investment in Altilium is to support the next phase of development of the planned ...

Bone-chilling temperatures couldn’t keep the crowds away from Takeda’s Kendall Square campus on Tuesday to celebrate a milestone for the Japanese drugmaker’s new R&D tower. More than 250 ...

In connection with the effectiveness of the agreement, Takeda will make an upfront payment to the Company of $200.0 million. About Keros Therapeutics, Inc. Keros is a clinical-stage ...

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), (OTCPK:AAPGV) which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing ...

See Correction/Clarification at the end of this article. After layoffs in 2024, Takeda is gearing up for a big 2025 that includes preparations to launch three new medicines, hiring, and finishing ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. “There's an evolution of our economic model that starts with [the] IRA (Inflation ...